Alopecia in patients treated with molecularly targeted anticancer therapies Journal Article
| Authors: | Belum, V. R.; Marulanda, K.; Ensslin, C.; Gorcey, L.; Parikh, T.; Wu, S.; Busam, K. J.; Gerber, P. A.; Lacouture, M. E. |
| Article Title: | Alopecia in patients treated with molecularly targeted anticancer therapies |
| Abstract: | Background: The introduction of molecularly targeted anticancer therapies presents new challenges, among which dermatologic adverse events are noteworthy. Alopecia in particular is frequently reported, but the true incidence is not known. Patients and methods: We sought to ascertain the incidence and risk of developing alopecia during treatment with approved inhibitors of oncogenic pathways and molecules [anaplastic lymphoma kinase, breakpoint cluster regionabelson, B-rapidly accelerated fibrosarcoma, Bruton's tyrosine kinase, cytotoxic T-lymphocyte antigen-4, epidermal growth factor receptor, human epidermal growth factor receptor-2, Janus kinase, MAPK/ERK (extracellular signalregulated kinase) Kinase, mammalian target of rapamycin, smoothened, vascular endothelial growth factor, vascular endothelial growth factor receptor, platelet derived growth factor receptor; proteasomes; CD20, CD30, CD52]. Electronic database (PubMed, Web of Science) and ASCO meeting abstract searches were conducted to identify clinical trials reporting alopecia. Meta-analysis was conducted utilizing fixed- or random-effects models. Results: The calculated overall incidence of all-grade alopecia was 14.7% [95% confidence interval (CI) 12.6% to 17.2%]-lowest with bortezomib, 2.2% (95% CI 0.4% to 10.9%), and highest with vismodegib, 56.9% (95% CI 50.5% to 63.1%). There was an increased risk of all-grade alopecia [relative risk (RR), 7.9 (95% CI 6.2-10.09, P ? 0.01)] compared with placebo, but when compared with chemotherapy, the risk was lower [RR, 0.32 (95% CI 0.2-0.55, P ? 0.01)]. Conclusions: Targeted therapies are associated with an increased risk of alopecia. © The Author 2015. |
| Keywords: | mitogen activated protein kinase; vasculotropin; sorafenib; erlotinib; placebo; sunitinib; drug efficacy; drug safety; solid tumor; antineoplastic agents; outcome assessment; antineoplastic agent; vasculotropin receptor; bortezomib; proteasome; incidence; epidermal growth factor receptor; epidermal growth factor receptor 2; platelet derived growth factor receptor; high risk patient; risk assessment; cd20 antigen; hematologic malignancy; systematic review; janus kinase; mammalian target of rapamycin; pazopanib; cytotoxic t lymphocyte antigen 4; alopecia; smoothened protein; meta analysis; cd52 antigen; cd30 antigen; targeted therapies; hair loss; non small cell lung cancer; anaplastic lymphoma kinase; thyroid medullary carcinoma; randomized controlled trial (topic); molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); adverse events; vismodegib; breakpoint cluster region protein; cabozantinib; bruton tyrosine kinase; regorafenib; human; priority journal; article; drug-induced alopecia |
| Journal Title: | Annals of Oncology |
| Volume: | 26 |
| Issue: | 12 |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-12-01 |
| Start Page: | 2496 |
| End Page: | 2502 |
| Language: | English |
| DOI: | 10.1093/annonc/mdv390 |
| PROVIDER: | scopus |
| PMCID: | PMC4658542 |
| PUBMED: | 26387145 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 7 January 2016 -- 2496 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work